Status:
COMPLETED
To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Quintiles, Inc.
Conditions:
Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.
Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
AZD2516 is being developed for the oral treatment of chronic neuropathic pain. This study is split in to two parts. Part A will measure the effect of food and a new formulation of the drug in the bloo...
Eligibility Criteria
Inclusion
- Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
- Healthy volunteers able and willing to comply with all study requirements.
Exclusion
- An ongoing or history of a medical or psychiatric disease/condition which may put the healthy volunteer at risk or interfere with the study objectives because of participation in the study, as judged by the investigator(s).
- History of psychotic disorder among first degree relatives.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01148095
Start Date
June 1 2010
End Date
July 1 2010
Last Update
February 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom